New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT03905148

First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 14 times

Summary

This early-stage study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The study is now complete, and results will help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, 2148, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, 6009, Australia

  • MD Anderson

    Houston, Texas, 77030, United States

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • The Prince of Wales Private Hospital - Specialist Medical Randwick

    Randwick, New South Wales, 2031, Australia

  • University of California Los Angeles

    Santa Monica, California, 90404, United States

Conditions

Explore the condition pages connected to this study.